These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23928731)

  • 1. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.
    Young BA; Spencer JF; Ying B; Tollefson AE; Toth K; Wold WS
    Cancer Gene Ther; 2013 Sep; 20(9):521-30. PubMed ID: 23928731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model.
    Young BA; Spencer JF; Ying B; Toth K; Wold WS
    Cancer Gene Ther; 2013 Sep; 20(9):531-7. PubMed ID: 23928730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters.
    Dhar D; Toth K; Wold WS
    Cancer Gene Ther; 2014 Apr; 21(4):171-8. PubMed ID: 24722357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.
    Dhar D; Spencer JF; Toth K; Wold WS
    J Virol; 2009 Mar; 83(5):2130-9. PubMed ID: 19073718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.
    Lamfers ML; Fulci G; Gianni D; Tang Y; Kurozumi K; Kaur B; Moeniralm S; Saeki Y; Carette JE; Weissleder R; Vandertop WP; van Beusechem VW; Dirven CM; Chiocca EA
    Mol Ther; 2006 Dec; 14(6):779-88. PubMed ID: 16996314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters.
    Hasegawa N; Abei M; Yokoyama KK; Fukuda K; Seo E; Kawashima R; Nakano Y; Yamada T; Nakade K; Hamada H; Obata Y; Hyodo I
    Int J Cancer; 2013 Sep; 133(6):1479-88. PubMed ID: 23444104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.
    Lichtenstein DL; Spencer JF; Doronin K; Patra D; Meyer JM; Shashkova EV; Kuppuswamy M; Dhar D; Thomas MA; Tollefson AE; Zumstein LA; Wold WS; Toth K
    Cancer Gene Ther; 2009 Aug; 16(8):644-54. PubMed ID: 19197324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.
    Thomas MA; Spencer JF; Toth K; Sagartz JE; Phillips NJ; Wold WS
    Mol Ther; 2008 Oct; 16(10):1665-73. PubMed ID: 18665155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.
    Ying B; Toth K; Spencer JF; Meyer J; Tollefson AE; Patra D; Dhar D; Shashkova EV; Kuppuswamy M; Doronin K; Thomas MA; Zumstein LA; Wold WS; Lichtenstein DL
    Cancer Gene Ther; 2009 Aug; 16(8):625-37. PubMed ID: 19197322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
    Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
    Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syrian hamster tumor model to study oncolytic Ad5-based vectors.
    Dhar D; Toth K; Wold WS
    Methods Mol Biol; 2012; 797():53-63. PubMed ID: 21948468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fully replication-competent adenovirus vector with enhanced oncolytic properties.
    Toth K; Kuppuswamy M; Shashkova EV; Spencer JF; Wold WS
    Cancer Gene Ther; 2010 Nov; 17(11):761-70. PubMed ID: 20596091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.
    Dhar D; Spencer JF; Toth K; Wold WS
    Mol Ther; 2009 Oct; 17(10):1724-32. PubMed ID: 19602998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
    Shashkova EV; Spencer JF; Wold WS; Doronin K
    Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
    Cerullo V; Diaconu I; Kangasniemi L; Rajecki M; Escutenaire S; Koski A; Romano V; Rouvinen N; Tuuminen T; Laasonen L; Partanen K; Kauppinen S; Joensuu T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Kanerva A; Pesonen S; Arstila PT; Hemminki A
    Mol Ther; 2011 Sep; 19(9):1737-46. PubMed ID: 21673660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity.
    Garofalo M; Iovine B; Kuryk L; Capasso C; Hirvinen M; Vitale A; Yliperttula M; Bevilacqua MA; Cerullo V
    Mol Cancer Ther; 2016 Apr; 15(4):651-60. PubMed ID: 26861248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
    Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
    Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling.
    Toth K; Djeha H; Ying B; Tollefson AE; Kuppuswamy M; Doronin K; Krajcsi P; Lipinski K; Wrighton CJ; Wold WS
    Cancer Res; 2004 May; 64(10):3638-44. PubMed ID: 15150123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.
    Dong W; van Ginkel JW; Au KY; Alemany R; Meulenberg JJ; van Beusechem VW
    Hum Gene Ther; 2014 Oct; 25(10):897-904. PubMed ID: 25093639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.